Preliminary results of transepithelial CXL in children with keratoconus were encouraging, with no evidence of progression of keratoconus over 12 months.

The Pascal photocoagulator is safe, rapid, effective, with rapid learning and had short exposure time. Although the shorter pulse duration of the Pascal necessitates the use of a higher power, it is not associated with adverse effects.

Background: Vitiligo is a common skin condition affecting 0.5-2% of the population. The exact etiology of the condition is unknown, but the result is autoimmune destruction of melanocytes. The eye is rich in melanocytes, especially in the retinal pigment epithelium and choroid. Little is known about the effect of vitiligo on the choroid of the eye. Methods: We cross-sectionally examined 31 right eyes of 31 vitiligo patients and 32 right eyes of 32 age-and sex-matched controls for signs of vitiligo affection and then measured the subfoveal choroidal thickness (SFCT) using spectral-domain optical coherence tomography. Results: There was a statistically significant difference between SFCT in the cases group and the control group (Mean ± SD: 251.9 ± 42.0 μm and 296.8 ± 46.4 μm, respectively, p = 0.0002). The thickness correlated negatively with age (r = −0.5) but did not correlate significantly with disease severity or duration (r = −0.201, −0.1781, p = 0.2783, 0.3381, respectively). Additional examination findings included iris and fundus hypopigmented spots, and peripapillary atrophy. Conclusion: SFCT is reduced among patients with vitiligo. The clinical implications of such a finding should be studied further, and eye screening programs should be considered.

Limbal stem cell transplantation together with conjunctival autografting proved to be more effective in prevention of pterygium recurrence and in rapid restoration of normal epithelial morphology. MMC in addition to AMT decreases the incidence of recurrence.

Purpose: To evaluate the efficacy and safety of intrasilicone injection of bevacizumab for the treatment of iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Methods: Bevacizumab 1.25 mg/0.05 ml was injected into silicone oil in 15 eyes of 11 patients with iris neovascularization which had developed 2.5–6 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of iris neovascularization, intraocular pressure elevation, and visual acuity. Results: In all eyes, iris neovascularization regressed and postinjection intraocular pressure was controlled within 7 days postinjection. Visual acuity improved in 12 eyes. In 4 patients, iris neovascularization recurred within 10 weeks after the injection and they were successfully treated with a second intrasilicone bevacizumab injection of the same dose. Conclusion: Intrasilicone injection of bevacizumab is safe and effective in the treatment of patients with iris neovascularization after vitrectomy for advanced proliferative diabetic retinopathy. Further studies on greater numbers of patients and more advanced neovascularization are recommended.

Aim: This study was done to evaluate the role of pentosidine in predicting the progression of diabetic retinopathy. Patients and Methods: We included 30 subjects with insulin-dependent diabetes mellitus (type 1) and 10 healthy control individuals. A case control study was done. Full ophthalmological examination together with laboratory investigations (blood glucose level, HbA_1C and blood pentosidine level corrected to blood total protein values were measured) were done in all subjects included in this study. The level of pentosidine was correlated with the duration of diabetes and the stage of retinopathy. All data were analyzed and reported. Results: Significant elevation of pentosidine was found in patients during the earliest detectable phase of diabetic retinopathy (early nonproliferative diabetic retinopathy) and more elevation at the preproliferative stage of retinopathy, returning to lower levels at the proliferative stage of diabetic retinopathy. Conclusion: Pentosidine can be used as a biochemical marker for early occurrence of diabetic retinopathy and as an alarming factor in the preproliferative stage of diabetic retinopathy, thus helping decrease ocular complications.

No abstract

Aim:To assess the changes in corneal hysteresis (CH) and corneal resistance factor (CRF) 1-year following transepithelial corneal collagen cross-linking (CXL) treatment in eyes of children with keratoconus.Methods:This case series was conducted in 22 eyes of 22 children. Children aged < 18 years with progressive keratoconus were included. They were treated with transepithelial CXL. Corneal biomechanical and anterior chamber parameters such as CH, CRF, and peak 1 were noted using ocular response analyzer, Pentacam, intraocular lens master, and anterior segment optical coherence tomography before and 1, 3, 6, and 12 months after treatment.Results:Our series had 22 eyes of 22 children with a mean age 15.7 ± 2.1 years. The CH and CRF 1-year after treatment declined (difference of mean 0.1 mmHg (95% confidence interval [CI] 0.04–0.24), P = 0.2] and (difference of mean 0.1 mmHg [95% CI 0.04–0.30], P = 0.3), respectively. Peak 1 and peak 2 increased (difference of mean 0.1 mmHg [95% CI 0.006–0.008], P = 0.2) and (difference of mean 0.1 mmHg [95% CI 0.007–0.006], P = 0.3), respectively. The uncorrected distance visual acuity improved from 0.95 ± 0.34 logMAR to 0.68 ± 0.45 logMAR (P < 0.05). No statistically significant changes during 12 months follow-up were observed in axial length, corneal volume, anterior chamber volume, and anterior chamber depth (P > 0.05).Conclusion:Transepithelial CXL in keratoconus in pediatric age group seems to have good stability in corneal biomechanical parameters after 1-year. Further studies with a larger sample and better study design are recommended to confirm our findings.